FDA Awards National Priority Vouchers to Three Psychedelic Programs, Compressing Review Times to One to Two Months
Compass Pathways, Usona Institute, and Otsuka-acquired Transcend Therapeutics have been selected for FDA's Commissioner's National Priority Voucher program for psilocybin and methylone, six days after President Trump's executive order on serious mental illness.
Overview
The U.S. Food and Drug Administration on April 24, 2026 awarded Commissioner’s National Priority Vouchers to three psychedelic drug programs, according to CNN: Compass Pathways’ synthetic psilocybin formulation for treatment-resistant depression, Usona Institute’s psilocybin candidate for major depressive disorder, and Transcend Therapeutics’ methylone-based program for post-traumatic stress disorder. The vouchers, per the agency, compress administrative review timelines from the standard ten months to roughly one or two months following a New Drug Application filing, without altering FDA’s evidentiary standards.
The announcement arrived six days after President Donald Trump signed an executive order directing federal health agencies to accelerate treatments for serious mental illness. According to the White House fact sheet, the April 18 order specifically instructs the FDA Commissioner to issue National Priority Vouchers to psychedelic drugs that already hold Breakthrough Therapy designations for serious mental illnesses. All three voucher recipients carry that designation.
The move marks the most concrete federal regulatory action yet on psychedelic medicines and follows a previously reported bipartisan Senate push to prepare the Department of Veterans Affairs for psychedelic-assisted therapies.
What We Know
The Three Voucher Recipients
Compass Pathways was the only one of the three voucher recipients to receive a simultaneous rolling NDA review designation, STAT News reports. The London-listed company has completed two late-stage studies of its synthetic psilocybin candidate, COMP360, that each enrolled hundreds of participants with treatment-resistant depression, BioPharma Dive reported. According to that coverage, COMP360 could become “the first ‘classic’ psychedelic cleared in the U.S.” if approved, with researchers reporting a statistically significant rapid onset starting the day after administration and lasting through six weeks. Compass expects 26-week durability data later this year.
The Wisconsin-based Usona Institute, a nonprofit medical research organization, received a voucher for its synthetic psilocybin candidate in major depressive disorder, per CNN. Usona’s program rests on a different evidentiary footing than Compass, and its NDA timeline has not been publicly committed.
The third voucher went to Transcend Therapeutics for TSND-201, a methylone-based program in development for PTSD, STAT News reports. Otsuka Pharmaceutical announced on March 27, 2026 that it had agreed to acquire Transcend for $700 million upfront and up to $525 million in contingent payments tied to future sales milestones. The deal, expected to close in the second quarter of 2026, would place TSND-201 within Otsuka’s psychiatric and neurological portfolio. Methylone is structurally related to MDMA but pursues a distinct safety and pharmacology profile; Otsuka describes it as a “rapid-acting neuroplastogen.”
What the Voucher Actually Does
The Commissioner’s National Priority Voucher program, launched in 2025, is intended to compress FDA review timelines from the standard ten to twelve months down to one to two months following NDA filing, according to CNN. The vouchers do not alter scientific or regulatory standards and do not guarantee approval; they govern administrative review pace. The FDA’s own announcement emphasized that the review pathway preserves the agency’s evidentiary requirements.
Compass had previously told STAT News in November 2025 that it expected an earlier FDA approval decision on its psilocybin drug than analysts had forecast, a timeline the new voucher and rolling review further compress. The voucher’s review window only begins after a complete or rolling NDA filing is accepted.
The Executive Order Behind the Vouchers
The vouchers implement directives from the April 18 executive order “Accelerating Medical Treatments for Serious Mental Illness.” The White House fact sheet lists five operational components: directing the FDA Commissioner to issue priority vouchers to qualifying psychedelics, establishing a pathway under the Right to Try Act for eligible patients to access investigational psychedelic compounds including ibogaine compounds, allocating $50 million through ARPA-H to match state investments in psychedelic research, expanding clinical trial coordination across HHS, FDA, and the Department of Veterans Affairs, and instructing the Attorney General to review Phase 3-completed products for potential DEA rescheduling. The order frames veterans, whose suicide rate the fact sheet describes as “more than twice as high as that of the non-veteran adult population,” as a primary intended beneficiary group; the same document notes “more than 6,000 veteran suicides per year” for over two decades.
A Notable Reversal
Compass had been blocked from a priority voucher by Trump administration officials in October 2025 when FDA Commissioner Marty Makary presented his proposed list for sign-off, STAT News reported in February, citing sources familiar with the process. Of ten drugs presented at the time, only Compass’ candidate was dropped from the final list approved by the Department of Health and Human Services. The April 24 selection reverses that earlier outcome and arrives alongside the FDA’s separate decision to allow a clinical study of noribogaine hydrochloride for alcohol use disorder to move forward, per the FDA’s announcement.
What We Don’t Know
The specific timing of each company’s NDA filing remains uncertain. Public guidance from Compass, as relayed by STAT News in November 2025, pointed to an accelerated approval timeline, but Usona and Transcend have not publicly committed to filing dates, and the voucher’s compressed review window only begins after a complete or rolling submission is accepted. Final FDA labeling, including whether psilocybin would carry restrictions tied to certified clinical environments, is also unresolved. Pricing, payer coverage, and DEA rescheduling steps fall outside the voucher process and will require separate determinations.
It is also unclear how the vouchers will interact with the parallel Right to Try framework established by the executive order, or how state-level psychedelic programs and the ARPA-H matching fund will be coordinated. Several psychedelic candidates with Breakthrough Therapy designation were not selected, and the FDA has not detailed the criteria distinguishing voucher recipients from other qualifying programs.
Why It Matters
For Compass, Usona, and the Otsuka-Transcend program, the vouchers shorten what would otherwise be a roughly year-long FDA review to a window measured in weeks once filings are complete. For the broader psychedelic field, the simultaneous award of three vouchers signals that the FDA is prepared to apply its fastest administrative track to a class of medicines that, until last year, was navigating a far slower path. Whether the compressed timeline produces approvals on schedule, and whether the resulting labels translate into broad clinical access, will determine how durable this regulatory shift proves to be.